Catabasis
Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage drug
development company built on a pathway pharmacology technology platform,
today announced that Catabasis will present an overview of the CAT-2000
program, the Company’s product candidate series targeting the Sterol
Regulatory Element-Binding Protein, or SREBP, pathway for the potential
treatment of hyperlipidemias, at the Kern Lipid Conference. The Kern
Lipid Conference will be held August 3 - 5, 2015, in Vail, Colorado at
the Vail Marriott Mountain Resort.
-
Joanne Donovan, M.D., Ph.D., chief medical officer of Catabasis, will
give a presentation titled “The CAT2000 program: Oral Modulators of
SREBP in Development for Hyperlipidemias.” The presentation will take
place on Monday, August 3, 2015, at 3:20 pm local time in the Grand
Ballroom, Salon F-J.
About CAT-2000
The CAT-2000 series are molecules engineered by Catabasis using its
proprietary Safely Metabolized And Rationally Targeted, or SMART, linker
technology platform to inhibit the maturation of Sterol Regulatory
Element-Binding Protein (SREBP) and reduce the expression of key
proteins involved in LDL-C and triglyceride metabolism. The CAT-2000
series include CAT-2054, CAT-2003, and other conjugates. In the CAT-2000
series, Catabasis’ development priority is CAT-2054 for the treatment of
hypercholesterolemia.
About Catabasis
Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of novel
therapeutics using its proprietary Safely Metabolized And Rationally
Targeted, or SMART, linker technology platform. The Company's SMART
linker technology platform is based on the concept of treating diseases
by simultaneously modulating multiple targets in one or more related
disease pathways. The Company engineers bi-functional product candidates
that are conjugates of two molecules, or bioactives, each with known
pharmacological activity, joined by one of its proprietary SMART
linkers. The SMART linker conjugates are designed for enhanced efficacy
and improved safety and tolerability. The Company’s focus is on
treatments for rare diseases. The Company is also developing other
product candidates for the treatment of serious lipid disorders. For
more information on the Company's technology and pipeline of drug
candidates, please visit www.catabasis.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150728005291/en/
Copyright Business Wire 2015